Korea Institute of Science and Technology

Korea Advanced Institute of Science and Technology

Seoul National University

Sungkyunkwan University

University-industry Cooperation Group of Kyung Hee University

Byung Hwa Jung

Jong Min Choi

Min-Jung Kang

Hong Seog Seo

Young Sook Yoo

Min Cheol Park

Dae Sik Jang

Soo Hyun Lee

Bong Chul Chung

Hocheol Kim

Hak Cheol Kwon

Bai Sun Kong

Hyun Ok Yang

Keon Wook Kang

Jeong Hill Park

Myung Soo Kim

Oh-Seung Kwon

Sung Won Kwon

Myung Sook Oh

Doheon Lee

Thanh Binh Nguyen

Hyun Beom Lee

Hafeza Akter

Won-Sang Park

Naeun Yoon

Sung Chan Kang

The present invention relates to a pharmaceutical composition for prevention or treatment of an allergic disease comprising a mixed extract of two or more selected from the group consisting ofroot,root, andas an active ingredient; a method for prevention or treatment of an allergic disease using the pharmaceutical composition; and a health functional food and a feed composition for improvement of an allergic disease. The composition and method of the invention can specifically inhibit the differentiation of Th2 cells and thus can be effectively used as a composition for prevention or treatment of an allergic disease.

Composition for preventing or treating allergic diseases containing mixed extract of two or more amongroot,root, andas active ingredients

A method, a composition and a kit for screening an ALK or ROS-1 kinase inhibitor are disclosed in the present specification. In an aspect, by the method, composition and kit for screening an ALK or ROS-1 kinase inhibitor according to the present disclosure, it is possible to conduct simultaneous quantitative and qualitative analysis and faster screening of a larger number of candidate substances as compared with conventional molecular biological experimental methods and to grasp the overall level of change in a plurality of different metabolites in a cell line by candidate substances of ALK or ROS-1 kinase inhibitor and thus the screening efficiency for drugs which exert an ALK or ROS-1 kinase inhibitory effect is excellent. Consequently, the present disclosure has an advantage of being able to be used in various ways in the development of new drugs which exert an ALK or ROS-1 kinase inhibitory effect.

Method, composition and kit for screening ALK or ROS-1 kinase inhibitor

Provided are a method of screening for novel therapeutic targets to develop therapeutic agents for colon cancer, and prognostic biomarkers for colon cancer treatment which are screened using the same.

Method of screening for novel therapeutic targets to develop therapeutic agents for colon cancer and prognostic biomarkers for colon cancer treatment screened using the same

The present disclosure relates to a method and a diagnostic kit for diagnosing stable angina and acute myocardial infarction early through simple blood testing and checking of clinical parameters. Unlike conventional diagnostic methods, stable angina can be diagnosed as distinguished from acute myocardial infarction according to the present disclosure by using one diagnostic platform based on the change in the in-vivo levels of biological metabolites having different metabolic pathways and clinical parameters as well as medications affecting the onset and progress of the disease through multivariable analysis.

Kit for diagnosis of coronary heart disease using multi-metabolites and clinical parameters, and method for diagnosis of coronary heart disease using the same

Rheumatoid arthritis is efficiently diagnosed with improved patient's convenience using a rheumatoid arthritis diagnosis composition and a kit, each including cyclic citrullinated peptide (CCP), a rheumatoid arthritis diagnosis method using the CCP, the rheumatoid arthritis diagnosis composition, or the kit, a method of obtaining information for rheumatoid arthritis diagnosis, and a method of screening a novel diagnostic marker for rheumatoid arthritis.

Cyclic citrullinated peptide, rheumatoid arthritis diagnosis composition including the same, rheumatoid arthritis diagnosis method using the peptide or the composition, and method of screening diagnostic marker for rheumatoid arthritis

The present disclosure provides a multi-metabolite platform using one or more metabolite selected from a group consisting of tryptophan, homoserine, fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2), fatty acid (22:6), phosphatidylcholine (PC) (34:2), PC (34:3), lysophosphatidylcholine (lysoPC) (16:0), lysoPC (18:0), lysoPC (20:3), lysoPC (20:4), lysoPC (22:6), monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0) as a biomarker, which can diagnose acute coronary syndrome as well as the symptoms occurring prior to the onset of the disease simply and accurately through in-vivo level analysis.

Multi-metabolites platform for diagnosis of acute coronary syndrome

Biological metabolites LysoPC (18:0), LysoPC (20:3), fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2) and fatty acid (22:6) according to the present disclosure allow for simple and accurate diagnosis of a cardiovascular disease since their level in the blood of a subject increases or decreases if the subject has a cardiovascular disease such as myocardial infarction or angina. In addition, whereas the existing biomarkers can diagnose only whether myocardial infarction occurs or not, the biological metabolites according to the present disclosure can diagnose not only myocardial infarction but also unstable angina occurring prior to the onset of myocardial infarction stage by stage.

Diagnostic method of cardiovascular disease

The present disclosure relates to stomach cancer diagnosis using tryptophan metabolism rate in one aspect, and it relates to an invention using change of tryptophan metabolism rate in a stomach cancer patient, which is different from a normal person.

Method for diagnosing stomach cancer using change of tryptophan metabolism

Provided are a composition of a diagnostic biomarker for stomach cancer and a method of diagnosing stomach cancer using the same. The composition of a diagnostic biomarker for stomach cancer and the method of diagnosing stomach cancer using the same may be useful to determine stomach cancer from a patient with suspected stomach cancer.

Composition of diagnostic biomarker for stomach cancer and method of diagnosing stomach cancer using the composition

Disclosed is a clock-based data storage device, which includes a dual pulse generating device and a data starge device having two dynamic nodes for prior chargement/dischargement. The clock-based data storage device includes a dual pulse generating unit which delays a clock signal and then outputs a first clock signal corresponding to inversion of a clock signal and a second clock signal corresponding to the clock signal by using the delayed clock signal when the clock signal shifts, a pull-up wait for outputting a pull-up output signal to an output port, based on the first clock signal outputted from the dual pulse generating unit and an input data signal which has beeb inputted, a pull-down unit for outputting a pull-down output signal to the output port, based on the second clock signal outputted from the dual pulse generating unit and the input data signal inputted which has been inputted, and a latch unit which is disposed between the pull-up and pull-down units, and the output port so as to store at least one output signal outputted from the pull-down unit as well as the pull-down unit.

Clock-based data storage device, dual pulse generation device, and data storage device

Disclosed is a method of extracting all metabolites existing in a biological sample to detect a comprehensive difference between metabolites of a control group and a test group, thereby verifying significance thereof. More particularly, the invention comprises a first step of analyzing a fraction extracted with a solid phase extraction method, a fraction obtained by extracting the remnant fraction with a liquid-liquid extraction method and fractions extracted with the liquid-liquid extraction method at two pH different from each other after the hydrolysis, with a gas chromatography-mass spectrometry; a second step of converting the chromatogram result into numerical values capable of being statistically processed; and a third step of analyzing the numerical values with a principal component analysis (PCA) and a discriminant analysis (DA) to detect a difference between the control group and the test group. According to the invention, the difference between the two groups can be comprehensively detected with the areas of the peaks on the chromatogram, without a standard material or verified quantitative method. Therefore, it is possible to detect the metabolic change in the organism due to the disease or gene mutation, without an accurate quantitative analysis of the metabolites.

Growing community of inventors

Seoul, South Korea

Byung Hwa Jung